Could Neuren Pharmaceuticals Be the Next Big Biotech Breakout After Daybues $700 million 2028 Forecast?

Source: Kapitales Research

Highlights:

• Neuren Pharmaceuticals Limited (ASX: NEU) jumped more than 5% after partner Acadia forecast Daybue sales could reach US$700 million by 2028 at the time of writing.
• The growth outlook is being driven by the U.S. rollout of the new STIX formulation, a larger sales force, and the potential for European regulatory approval.
• Rising Daybue sales could significantly lift Neuren’s royalty income and long-term earnings outlook, strengthening investor confidence in the stock.

Neuren Pharmaceuticals Limited (ASX: NEU) saw its shares rally sharply after its partner Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) forecast that global net sales for the Rett syndrome treatment Daybue could reach about US$700 million by 2028 — a massive growth story driven by new formulations, expanded U.S. sales teams, and possible European approval at the time of writing.

Strong Sales Outlook Fuels Share Gains

Shares of Neuren climbed more than 5 per cent in early trading following the upbeat projection from Acadia, as investors reacted positively to the potential revenue upside tied to Daybue’s growth. According to market reports, investors are increasingly optimistic about Neuren’s earnings trajectory as royalties from Daybue sales rise. Acadia’s forecast breaks down to approximately US$700 million in net sales for Daybue by 2028, supported by the U.S. rollout of the new Daybue STIX formulation expected to broaden patient adoption, and progress toward regulatory approvals in Europe and other markets.

Daybue Momentum: What’s Driving Growth?

Daybue (trofinetide) is approved in the U.S. for Rett syndrome, a rare neurodevelopmental disorder, and its commercial performance has steadily improved since launch. The introduction of the STIX powder formulation, anticipated to expand patient access and convenience, is a key catalyst for future sales growth. Additionally, Acadia’s broader global strategy includes potential marketing approvals in Europe and ongoing clinical development efforts that could unlock even more markets and patients — all of which boosts royalty potential for Neuren.

Broader Impacts and Future Prospects

The projected growth to US$700 million by 2028 places Daybue among the fastest-growing therapies in the rare-disease segment, significantly enhancing Neuren’s revenue streams. Expansion beyond the U.S., especially in Europe and Asia, remains a critical driver in the coming years.

At the time of writing, this development is gaining traction across financial news outlets and biotech market watchers, highlighting Neuren’s rising profile amid strong commercial execution by Acadia.

Bottom Line

With a compelling sales forecast for Daybue and ongoing regulatory and commercial momentum, Neuren Pharmaceuticals could be one to watch for investors focused on biotech growth stories in 2026 and beyond.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au